特宝生物新品上市助业绩八连增 五年分红5.67亿为融资额1.5倍

Core Viewpoint - The company Teva Biopharma (688278.SH) has demonstrated robust growth in its operating performance, achieving record highs in revenue and net profit for 2025, driven by stable sales of key products and new product approvals [1][2]. Financial Performance - In 2025, Teva Biopharma reported revenue of 3.696 billion yuan, a year-on-year increase of 31.18%, and a net profit attributable to shareholders of 1.038 billion yuan, marking a 25.38% increase and the first time surpassing the 1 billion yuan mark [2][4]. - The company achieved revenue and net profit of 2.480 billion yuan and 666 million yuan respectively in the first three quarters of 2025, reflecting year-on-year growth of 26.85% and 20.21% [2]. - In the fourth quarter of 2025, revenue and net profit reached 1.216 billion yuan and 372 million yuan, showing significant growth of 41.07% and 36.26% year-on-year [2][3]. Consistent Growth - Teva Biopharma has experienced continuous growth in revenue and net profit for eight consecutive years from 2018 to 2025, with revenue increasing from 448 million yuan in 2018 to over 3 billion yuan in 2025 [1][3]. - The net profit has also shown substantial growth, increasing from 16 million yuan in 2018 to 1.038 billion yuan in 2025, representing a growth of 787.18% compared to 2020 [4]. Product Development - The company focuses on the clinical cure of hepatitis B, having launched six drugs and one electronic pen injector by June 2025 [1][6]. - Teva Biopharma's key product, Pegbavirin, is recognized as the first drug globally targeting clinical cure for hepatitis B, further solidifying its position in the market [3][6]. Research and Development - R&D investment has been on the rise, with 312 million yuan spent in the first three quarters of 2025, reflecting a year-on-year increase of 38.67% [1][7]. - The company has completed nine major new drug creation projects under national technology initiatives, with several innovative drugs currently in clinical research [7]. Shareholder Returns - Since its listing in 2020, Teva Biopharma has consistently returned value to shareholders, distributing a total of 567 million yuan in dividends over five years, which is 1.5 times its equity financing amount [1][7].